GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
The Firm is investigating GranuFlo recall lawsuits on behalf of dialysis patients who suffered heart attacks, strokes, and other life-threatening heart problems within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte dialysis concentrates.
New York, New York (PRWEB) September 20, 2013
Hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed on behalf of patients who allegedly suffered serious heart problems related to the 2012 recall of GranuFlo and NaturaLyte dialysis concentrates continue to move forward in the federal multidistrict litigation in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the Court will convene a Status Conference on September 27, 2013. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm hears from dialysis patients affected by the GranuFlo recall on a regular basis. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.
GranuFlo Recall Lawsuits
Both GranuFlo and NaturaLyte are marketed by Fresenius Medical Care and used during dialysis to remove toxins from the blood. According to The New York Times, prior to the GranuFlo recall, both were widely used at Fresenius’ own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network. *
In March of 2012 Fresenius issued an Urgent Product Notification to dialysis clinics across the country after GranuFlo and NaturaLyte were linked to a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. Several months later, the U.S. Food & Drug Administration (FDA) deemed the notification a Class I GranuFlo recall, a designation that is only granted when a medical product poses a significant risk of serious injury or death. According to the Times, the FDA later launched an investigation of Fresenius Medical Care shortly after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. The agency is trying to determine if Fresenius’ delay in notifying dialysis clinics outside of its network violated any federal regulations.*
Court records indicate that more than 300 GranuFlo lawsuits have been filed in courts throughout the U.S., all of which allege that Fresenius Medical Care failed to provide adequate warnings regarding the use of the products, and assert that the company continued to aggressively market GranuFlo and NaturaLyte even after the company became aware of their dangers. In addition to the federal litigation, GranuFlo lawsuits have also been consolidated at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)
Dialysis patients who suffered sudden and life-threatening heart problems, including cardiac arrest, heart attacks, stroke, and sudden cardiac death, within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation for their injury-related damages. Click Here to learn how to contact a GranuFlo lawyer at Bernstein Liebhard LLP. For additional information, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11146129.htm